Shares of AVITA Medical Inc. (RCEL) are down over 50% from their 52-week high of $14.16, recorded in January of this year, to trade around $7.
This therapeutic acute wound care company's flagship product is the RECELL System, an autologous cell harvesting device intended for use at the point of care by a trained health care professional. It enables the collection of a small skin sample, which is then used to create a suspension of Spray-On Skin Cells for treatment. The device is approved by the FDA for the treatment of thermal burn wounds and full-thickness skin defects.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com